The gap between clinical trial efficacy and real-world effectiveness often disappoints patients and clinicians when promising treatments reach everyday practice. This disconnect has been particularly concerning for treatment-resistant depression, where patients have exhausted multiple therapeutic options and desperately need interventions that work outside controlled research settings.
A comprehensive meta-analysis examining nine real-world studies reveals that intranasal esketamine maintains remarkable effectiveness in clinical practice, achieving a Hedges' g effect size of -1.98 for depressive symptom reduction. This effect magnitude substantially exceeds typical antidepressant responses and approaches what researchers consider large clinical impact. Patients demonstrated five-fold higher likelihood of achieving remission at three months compared to treatment initiation phases, with effectiveness remaining consistent across demographic groups and comorbidity profiles including anxiety, personality disorders, and substance use conditions.
This evidence addresses critical questions about esketamine's translation from research to practice. Unlike many psychiatric medications that show attenuated benefits in real-world settings, esketamine appears to retain its therapeutic potency when administered in routine clinical environments. The consistency across diverse patient populations suggests robust mechanisms of action that transcend the controlled conditions of randomized trials. However, the meta-analysis draws from observational studies without control groups, limiting causal inferences. The real-world evidence nonetheless provides reassuring validation for clinicians treating the most challenging depression cases, where conventional therapies have failed and rapid-acting interventions represent crucial therapeutic lifelines.